PL1904099T3 - Emulsja immunologiczna współdziałająca - Google Patents

Emulsja immunologiczna współdziałająca

Info

Publication number
PL1904099T3
PL1904099T3 PL06778810T PL06778810T PL1904099T3 PL 1904099 T3 PL1904099 T3 PL 1904099T3 PL 06778810 T PL06778810 T PL 06778810T PL 06778810 T PL06778810 T PL 06778810T PL 1904099 T3 PL1904099 T3 PL 1904099T3
Authority
PL
Poland
Prior art keywords
thermoreversible
immuno
adjuvant emulsion
adjuvant
emulsion
Prior art date
Application number
PL06778810T
Other languages
English (en)
Inventor
Marie-Françoise Klucker
François Dalencon
Patricia Probeck-Quellec
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/fr
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of PL1904099T3 publication Critical patent/PL1904099T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
PL06778810T 2005-07-07 2006-07-07 Emulsja immunologiczna współdziałająca PL1904099T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (fr) 2005-07-07 2005-07-07 Composition vaccinale comprenant une emulsion thermoreversible
FR0508310 2005-08-04
PCT/FR2006/001635 WO2007006939A2 (fr) 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoreversible
EP06778810A EP1904099B1 (fr) 2005-07-07 2006-07-07 Emulsion immuno-adjuvante thermoréversible

Publications (1)

Publication Number Publication Date
PL1904099T3 true PL1904099T3 (pl) 2009-08-31

Family

ID=37637538

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06778810T PL1904099T3 (pl) 2005-07-07 2006-07-07 Emulsja immunologiczna współdziałająca
PL09152313T PL2080522T3 (pl) 2005-07-07 2006-07-07 Termoodwracalna immuno-adjuwant-emulsja

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09152313T PL2080522T3 (pl) 2005-07-07 2006-07-07 Termoodwracalna immuno-adjuwant-emulsja

Country Status (24)

Country Link
EP (2) EP2080522B1 (pl)
JP (1) JP5300475B2 (pl)
KR (1) KR101328638B1 (pl)
CN (1) CN101217977B (pl)
AR (1) AR054822A1 (pl)
AT (1) ATE424845T1 (pl)
AU (1) AU2006268466B2 (pl)
BR (1) BRPI0614053A2 (pl)
CA (1) CA2613732C (pl)
CY (2) CY1108994T1 (pl)
DE (1) DE602006005671D1 (pl)
DK (2) DK2080522T3 (pl)
EA (1) EA012376B1 (pl)
ES (2) ES2322102T3 (pl)
IL (1) IL187967A0 (pl)
MX (1) MX2007016412A (pl)
NO (1) NO336369B1 (pl)
NZ (1) NZ564173A (pl)
PL (2) PL1904099T3 (pl)
PT (2) PT2080522E (pl)
SG (1) SG163584A1 (pl)
SI (2) SI1904099T1 (pl)
TN (1) TNSN08001A1 (pl)
WO (1) WO2007006939A2 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052155A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
AU2008269721B2 (en) * 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
KR101707569B1 (ko) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
KR101725196B1 (ko) 2009-02-25 2017-04-10 스티펠 리서치 오스트레일리아 피티와이 리미티드 국소 폼 조성물
CA2776874A1 (en) 2009-10-09 2011-04-14 Cbio Limited Chaperonin 10 variants
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
NZ630807A (en) 2012-03-23 2016-04-29 Pitney Pharmaceuticals Pty Ltd Kinase inhibitors for the treatment of cancer
US20150150963A1 (en) 2012-06-05 2015-06-04 The Australian National University Vaccination with interleukin-4 antagonists
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CA2878599A1 (en) 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
KR102124392B1 (ko) 2012-08-06 2020-06-19 피트니 파마슈티컬스 피티와이 리미티드 mTOR 경로 관련 질병 치료를 위한 화합물
CN103784953B (zh) * 2012-10-26 2018-04-10 上海医药工业研究院 作为疫苗佐剂的水包油型亚微乳及其制备方法
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
ES2727686T3 (es) 2012-12-17 2019-10-17 Newsouth Innovations Pty Ltd Tratamiento de enfermedades que implican mucina
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
CN105267962A (zh) * 2014-06-18 2016-01-27 潘皓 纳米乳疫苗辅剂
BR112016031039B1 (pt) 2014-07-21 2022-02-15 Sanofi Pasteur Sa Dispositivo de alimentação de líquido para a geração de gotículas, linha de processo para a produção de partículas liofilizadas e processos para preparar uma composição de vacina compreendendo
AU2016236770B2 (en) 2015-03-26 2022-03-10 Gpn Vaccines Pty Ltd Streptococcal vaccine
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
RU2018137034A (ru) * 2016-03-23 2020-04-23 Интервет Интернэшнл Б.В. Комбинированная вакцина против вируса pcv2 и инфекции mycoplasma hyopneumoniae
EP3498263B1 (en) * 2016-08-10 2023-11-29 Celltrion Inc. Stable liquid pharmaceutical preparation for anti-influenza virus antibody
BR112019019813A2 (pt) 2017-03-30 2020-04-22 The University Of Queensland moléculas quiméricas e usos das mesmas
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
CA3190368A1 (en) 2020-08-24 2022-03-03 Natalie ANOSOVA Vaccines against sars-cov-2 infections
JP2026504797A (ja) 2023-03-02 2026-02-10 サノフィ・パスツール クラミジア（Ｃｈｌａｍｙｄｉａ）の治療に使用するための組成物
CN118662475B (zh) * 2023-03-16 2026-02-06 清华大学 固体化自微乳疫苗的制备与应用
WO2024231727A1 (en) 2023-05-05 2024-11-14 Sanofi Compositions for use in treatment of acne
CN116531514A (zh) * 2023-05-29 2023-08-04 大连理工大学 一种烷基糖苷表面活性剂在铝佐剂冻干中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
AU641121B2 (en) 1988-01-29 1993-09-16 Chiron Corporation Recombinant CMV neutralizing proteins
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US6995209B2 (en) * 2001-03-21 2006-02-07 Madash Llc Thermally reversible water in oil in water emulsions
AR054822A1 (es) * 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
AU2006268466A1 (en) 2007-01-18
AR054822A1 (es) 2007-07-18
CN101217977B (zh) 2013-03-06
ATE424845T1 (de) 2009-03-15
EP2080522B1 (fr) 2012-07-04
BRPI0614053A2 (pt) 2011-03-09
PL2080522T3 (pl) 2012-11-30
EP2080522A1 (fr) 2009-07-22
IL187967A0 (en) 2008-03-20
WO2007006939A3 (fr) 2007-04-05
SG163584A1 (en) 2010-08-30
CY1113414T1 (el) 2016-06-22
PT1904099E (pt) 2009-05-29
DE602006005671D1 (en) 2009-04-23
KR101328638B1 (ko) 2013-11-27
KR20080030076A (ko) 2008-04-03
EP1904099B1 (fr) 2009-03-11
JP2009500382A (ja) 2009-01-08
WO2007006939A2 (fr) 2007-01-18
SI1904099T1 (sl) 2009-08-31
ES2322102T3 (es) 2009-06-16
CY1108994T1 (el) 2014-07-02
NO20080585L (no) 2008-03-26
EA012376B1 (ru) 2009-10-30
CA2613732A1 (en) 2007-01-18
PT2080522E (pt) 2012-10-01
CN101217977A (zh) 2008-07-09
CA2613732C (en) 2013-12-10
EA200800271A1 (ru) 2008-04-28
AU2006268466B2 (en) 2011-11-10
JP5300475B2 (ja) 2013-09-25
NO336369B1 (no) 2015-08-10
DK1904099T3 (da) 2009-06-08
SI2080522T1 (sl) 2012-10-30
TNSN08001A1 (fr) 2009-07-14
DK2080522T3 (da) 2012-10-08
ES2390104T3 (es) 2012-11-06
NZ564173A (en) 2010-10-29
MX2007016412A (es) 2008-03-07
EP1904099A2 (fr) 2008-04-02

Similar Documents

Publication Publication Date Title
IL187967A0 (en) Thermoreversible immuno-adjuvant emulsion
ZA200805651B (en) Thermoreversible oil-in-water emulsion
ZA200804923B (en) Induced-viscosity nutritional emulsions
PL1584370T3 (pl) Emulgator
PL2067627T3 (pl) Drukarka
GB0409940D0 (en) Vaccine
MX2008006197A (en) High Sunscreen Efficiency Water-in-Oil Emulsion
GB0507468D0 (en) Emulsion separator
GB0411150D0 (en) Vaccine
GB0401101D0 (en) Dispersions
GB0406021D0 (en) Document assembly apparatus
GB0404403D0 (en) Dispersions
EP1707485A4 (en) PROPELLER
GB2420562B (en) Emulsion ink
GB0424697D0 (en) Propeller design
GB0412407D0 (en) Vaccine
GB2417709B (en) Document
ZA200800824B (en) Themoreversible immuno-adjuvant emulsion
GB2418155B (en) Emulsion macadam
GB0524022D0 (en) Emulsions
GB0406598D0 (en) Vaccine
AP2709A (en) An anti-theileriosis vaccine
GB2422375B (en) Emulsion ink
PL368766A1 (pl) Śmigło
GB0508331D0 (en) Propeller